ALQA has been the subject of a number of other reports. Chardan Capital reissued a buy rating on shares of Alliqua in a report on Sunday, July 10th. Zacks Investment Research cut Alliqua from a buy rating to a hold rating in a report on Friday, August 12th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Alliqua presently has a consensus rating of Buy and a consensus target price of $2.50.
Shares of Alliqua (NASDAQ:ALQA) opened at 0.84 on Friday. The firm’s market cap is $24.93 million. The company has a 50 day moving average of $0.88 and a 200-day moving average of $1.00. Alliqua has a 12-month low of $0.70 and a 12-month high of $3.82.
Alliqua (NASDAQ:ALQA) last issued its quarterly earnings data on Tuesday, August 9th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.32. The company earned $5.50 million during the quarter, compared to analysts’ expectations of $5.38 million. Alliqua had a negative return on equity of 53.07% and a negative net margin of 73.41%. Equities research analysts forecast that Alliqua will post ($0.72) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its position in Alliqua by 589.0% in the first quarter. Renaissance Technologies LLC now owns 137,800 shares of the company’s stock worth $113,000 after buying an additional 117,800 shares in the last quarter. US Bancorp DE boosted its position in Alliqua by 29.8% in the second quarter. US Bancorp DE now owns 181,732 shares of the company’s stock worth $204,000 after buying an additional 41,732 shares in the last quarter. Vanguard Group Inc. boosted its position in Alliqua by 1.1% in the second quarter. Vanguard Group Inc. now owns 524,296 shares of the company’s stock worth $587,000 after buying an additional 5,780 shares in the last quarter. Finally, Suffolk Capital Management LLC boosted its position in Alliqua by 18.0% in the second quarter. Suffolk Capital Management LLC now owns 1,206,127 shares of the company’s stock worth $1,351,000 after buying an additional 184,274 shares in the last quarter. 29.89% of the stock is owned by institutional investors and hedge funds.
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
Receive News & Ratings for Alliqua Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Inc. and related companies with MarketBeat.com's FREE daily email newsletter.